<DOC>
	<DOCNO>NCT01470729</DOCNO>
	<brief_summary>Autosomal dominant cerebellar ataxia ( ADCA ) group neurodegenerative disorder clinically genetically various . BIOSCA study aim identify marker metabolism ( energy production inside cell ) blood brain ADCA 1,2,3 7 patient control subject , perspective future therapeutic trial .</brief_summary>
	<brief_title>Biomarkers Autosomal Dominant Cerebellar Ataxia</brief_title>
	<detailed_description>Rational . Autosomal dominant cerebellar ataxia ( ADCA ) clinically heterogeneous group neurodegenerative disorder cause unstable CAG repeat expansion encode polyglutamine tract . ADCA wide range neurological symptom include ataxia gait , stance , limb , cerebellar dysarthria , oculomotor disturbance cerebellar supranuclear genesis , retinopathy , optic atrophy , spasticity , extra-pyramidal movement disorder , peripheral neuropathy , sphincter disturbance , cognitive impairment , epilepsy . Corresponding neuropathological finding hereditary ataxia , three fundamental pattern degeneration MRI : spinal atrophy , olivopontocerebellar atrophy , cortical cerebellar atrophy . We previously show hypercatabolism premanifest early stage Huntington 's disease ( HD ) , along systemic metabolic defect : progressive decrease plasmatic branched-chain amino acid ( BCAA ) - correlate low serum IGF1 ( insulin-like growth factor 1 ) - muscle energy metabolism abnormality measure 31P-NMR spectroscopy . We also observe weight loss SCA1 , 3 mostly SCA7 patient . In addition , underlined preliminary study significant decrease BCAA SCA1,2,3 7 patient , suggest energy deficit would also imply SCA pathogenesis . Transcriptional interference likely part SCA physiopathology , show retinal cell SCA7 mouse model , detect cerebellum growth mouse . The hallmark gene expression study SCA1 SCA7 mouse point implication IGF1 pathway IGF1 receptor . As HD , transcriptional disorder might witness metabolic defect above-mentioned . Study objectives . The primary aim study provide metabolic image biomarkers SCA1,2,3 7 patient control perspective future therapeutic trial . The secondary aim determine ( ) systemic energy profile SCA1,2,3 7 patient confirmation hypercatabolic status , ( ii ) brain energy profile SCA1,2,3 7 patient measure vivo 31P-NMR spectroscopy . Study population . BIOSCA recruit 120 participant Pitie Salpetriere University Hospital locate Paris , France . The target cohort 80 patient - divide 4 group 20 participant mutation - 40 control . Study design . All patient ( SCA1,2,3,7 ) assess baseline ( visit 1 ) , 1 year ( visit 2 ) 2 year ( visit 3 ) . At visit 1 3 , subject undergo clinical , MRI , bone mineral density rest metabolic rate assessment , well donate fast blood sample . Each visit last approximately 6 hour . At visit 2 , clinical assessment along fast blood sample . Control subject see visit 1 3 assessment patient . Study period . BIOSCA prospective study participant enrol 24 month . The study duration 36 month . The start date November 2011 . Funding . BIOSCA fund national funding hospital program clinical research ( PHRC ) APHP institution .</detailed_description>
	<mesh_term>Ataxia</mesh_term>
	<mesh_term>Cerebellar Ataxia</mesh_term>
	<mesh_term>Spinocerebellar Ataxias</mesh_term>
	<mesh_term>Spinocerebellar Degenerations</mesh_term>
	<criteria>Inclusion criterion : More 18 year age Ability tolerate MRI Positive genetic test SCA1 , 2 , 3 7 Coverage social insurance Written inform consent must obtain subject Exclusion criterion : Less 18 year age Concomitant significant neurological disorder Unsuitability MRI , e.g . claustrophobia , metal implant History significant head injury Unability receive inform explanation protocol Unability complete protocol Non coverage social insurance No write informed consent obtain</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Spinocerebellar ataxia , energy metabolism , NMR spectroscopy</keyword>
</DOC>